Workflow
热景生物(688068) - 2020 Q1 - 季度财报
HotgenHotgen(SH:688068)2020-04-22 16:00

Financial Performance - Net profit attributable to shareholders was CNY 512,677.27, a 127.78% increase from a loss of CNY 1.84 million in the same period last year[7]. - Operating revenue rose by 3.64% to CNY 38.37 million, compared to CNY 37.02 million in the previous year[7]. - Basic earnings per share improved to CNY 0.01 from a loss of CNY 0.04, representing a 125.00% increase[7]. - Operating profit for Q1 2020 was CNY 749,266.95, a significant recovery from a loss of CNY 2,186,142.52 in Q1 2019[36]. - Total comprehensive income for Q1 2020 was ¥512,677.27, a recovery from a loss of ¥1,845,449.80 in Q1 2019[40]. - Net profit for Q1 2020 reached ¥1,373,553.96, compared to a net loss of ¥680,185.03 in the same period last year[40]. Cash Flow - The net cash flow from operating activities improved by 18.57% to CNY -8.17 million, compared to CNY -10.03 million in the same period last year[7]. - Cash inflow from operating activities was ¥72,844,750.38 in Q1 2020, up from ¥40,975,495.49 in Q1 2019, indicating strong operational cash generation[42]. - The net cash flow from operating activities for Q1 2020 was -4,910,687.58 RMB, an improvement from -12,892,133.01 RMB in Q1 2019, indicating a reduction in losses[44]. - The company reported a net decrease in cash and cash equivalents of -111,280,027.93 RMB for Q1 2020, compared to -42,460,075.11 RMB in Q1 2019[45]. Assets and Liabilities - Total assets increased by 4.00% to CNY 754.70 million compared to the end of the previous year[7]. - Total liabilities increased to CNY 102,291,691.62 in Q1 2020, compared to CNY 77,354,373.10 in Q1 2019, reflecting a growth of 32.3%[32]. - The company’s inventory increased from CNY 66,172,032.17 at the end of 2019 to CNY 79,354,158.96, representing a growth of about 19.9%[27]. - The company’s accounts payable increased from CNY 11,684,113.64 at the end of 2019 to CNY 14,492,654.72, an increase of about 23.9%[28]. Research and Development - Research and development expenses accounted for 22.42% of operating revenue, an increase of 3.62 percentage points from 18.80%[7]. - Research and development expenses for Q1 2020 were CNY 8,603,241.32, an increase of 23.5% compared to CNY 6,961,299.38 in Q1 2019[36]. - The company added 6 new authorized patents during the reporting period, including 1 invention patent and 1 international PCT patent[20]. Shareholder Information - The total number of shareholders reached 6,076 by the end of the reporting period[12]. - The top shareholder, Lin Changqing, holds 23.55% of the shares, totaling 14,650,329 shares[12]. Expenses - The company reported a 30.31% increase in management expenses, rising from CNY 5,120,915.13 to CNY 6,673,089.35[19]. - Financial expenses increased by 139.93% from CNY 120,395.30 to CNY 288,865.58, attributed to interest expenses on office building loans[19]. - Sales expenses were reduced to ¥14,647,603.53 in Q1 2020 from ¥16,409,499.55 in Q1 2019, contributing to improved profitability[40]. Government Subsidies and Tax - The company reported a government subsidy of CNY 96,300, which is included in the non-operating income[10]. - The company’s income tax expense was CNY 752,308.41, a significant increase compared to a tax benefit of CNY -204,381.92 in the previous year[19]. Other Financial Metrics - The weighted average return on net assets increased by 0.96 percentage points to 0.08%[7]. - The company’s retained earnings increased to CNY 124,118,692.20 from CNY 123,606,014.93, showing a growth of 0.4%[32]. - Deferred income tax liabilities rose to CNY 1,088,089.24 from CNY 997,530.34, reflecting an increase of 9.1%[32].